摘要
为观察枯草杆菌二联活菌肠溶胶囊联合泮托拉唑治疗溃疡性结肠炎患者的疗效,将溃疡性结肠炎患者98例随机分为对照组和观察组,每组49例。对照组患者采用泮托拉唑钠肠溶胶囊治疗,观察组患者在对照组治疗的基础上联合枯草杆菌二联活菌肠溶胶囊治疗,观察比较2组患者治疗后的临床疗效、临床症状评分、炎症因子水平及不良反应。结果显示,观察组患者总有效率为93.88%,显著高于对照组的75.51%(P<0.05);治疗后观察组患者临床症状评分显著低于对照组(P<0.05);治疗后观察组患者白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)水平显著低于对照组(P<0.05)。观察组患者治疗后不良反应总发生率为8.16%,显著低于对照组的24.49%(P<0.05)。结果表明,枯草杆菌二联活菌肠溶胶囊联合泮托拉唑治疗溃疡性结肠炎能提高患者临床疗效,缓解临床症状,降低炎症因子水平及不良反应发生率。
This study was to investigate the effect of Bacillus subtilis bivaccine living bacteria enteric-coated capsule(shortly named as "capsule")combined with pantoprazole in the treatment of ulcerative colitis(UC),randomly divided 98 UC patients into control group(49 cases,administered pantoprazole capsule)and observation group(49 cases,above combined medication);then observed and compared both groups’ clinical effect,the score on symptoms,the level of inflammatory factor(IF),and untoward reaction incidence.As results,in total clinical effect rate,the score on symptoms after treatment,the level of IF(IL-8,TNF-α),as well untoward reaction incidence,observation group was respectively and significantly higher(93.88% vs 75.5%),lower,lower as well lower than control group(all,P<0.05).Results show that above combined medication for treating UC can enhance effect,reduce symptoms,decline IF levels and untoward reaction incidence.
作者
周芳芳
ZHOU Fang-fang(Pharmacy Intra venous Admixture Services,the Luoyang Central Hospital Affiliated to Zhengzhou University,Luoyang,Henan 471000)
出处
《中国肛肠病杂志》
2019年第10期33-35,共3页
Chinese Journal of Coloproctology
关键词
溃疡性结肠炎
枯草杆菌
二联活菌肠溶胶囊
泮托拉唑
Ulcerative colitis
Bacillus subtilis
Bivaccine living bacteria enteric-coated capsule
Pantoprazole
